Key Treatment Topicsa Patients Wanted HCPs to Discuss More (n=1301)b

Select Country1

  • Italy (n=162)
  • Germany (n=207)
  • France (n=256)
  • Spain (n=115)
  • UK (n=130)
  • Japan (n=126)
  • US (n=305)
  • Impact on mental health or emotional wellbeing
  • Resources for treatment logistical challenges
  • Clinical trial eligibility
  • Effects of current treatment choices on future treatment
  • Quickly identifying side effects and taking action
  • Impact of side effects on everyday life and activities
  • Clinical trial side effect and safety data
  • Direct treatment costs
  • Indirect treatment costsc
  • Needs after treatmentd

aDefined as topics reported by at least 40% of patients to not be discussed enough by their HCPs. bLanguage of some responses has been simplified from survey prompt. cIndirect costs are defined as costs outside of the treatment itself, eg, travel costs and missed work. dIncluding any additional care needed.
HCP, health care professional.

Reference

  1. Popat R, Clavreul S, Greenwood A, et al. Understanding different treatment (Tx) goals and experiences according to characteristics in relapsed/refractory multiple myeloma (RRMM). Presented at: 22nd IMS Annual Meeting; September 17-20, 2025; Toronto, Canada. Poster PA-483.